# Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy

Source: https://onco.cc/trials/nct06034197/  
OnCo record `nct06034197` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Abenacianine run by Stephan Rogalla, terminated.

## Summary

Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy is a phase 1 interventional study registered as NCT06034197 by Stephan Rogalla, with 9 participants enrolled, started 2024-02-07. Conditions recorded: Colorectal Cancer. Interventions recorded: VGT-309.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06034197
- Phase: 1
- Setting: Pilot Open Label Study to Determine the Safety and Efficacy of Fluorescent Probe, VGT-309, to Identify Cancerous Colorectal Lesions During White-Light and Fluorescence Augmented Colonoscopy
- Sponsor: Stephan Rogalla
- Enrolled: 9

## Sources

- ClinicalTrials.gov NCT06034197: https://clinicaltrials.gov/study/NCT06034197

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Abenacianine](https://onco.cc/drugs/abenacianine/)
- companies: [Vergent Bioscience](https://onco.cc/companies/vergent-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/nct06034197.json